Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$1.19
-$0.03(-3.56%)
At close: 4:00 PM EST
$1.19
-$0.03(-3.56%)
Day’s Range― - ―
52-Week Range$0.55 - $3.83
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.91M
Market Cap
$84.13M
Enterprise Value$36.98
Total Cash (Recent Filing)$31.13M
Total Debt (Recent Filing)$465.00K
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding89,498,020
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Positive EquityExtremely low debt and a positive equity base provide structural financial flexibility for a development-stage biotech. Lower interest obligations reduce cash strain and preserve optionality to prioritize R&D spending or negotiate non-dilutive funding, supporting program continuity over months.
Productive FDA Meeting Guiding Phase 3 PathRegulatory alignment from a productive FDA discussion materially reduces development risk by clarifying trial design and endpoints for a registrational study. This durable de-risking improves the probability of efficient late‑stage development and can shorten timelines and costs versus unclear regulatory paths.
Robust Phase 2 Signals And Grant-funded START TrialStrong Phase 2 efficacy signals in DLB and a grant‑funded Alzheimer’s Phase 2 reduce technical and near‑term financing risk. Efficacy evidence plus external funding both increase the chance of advancing to registrational studies while conserving cash runway and preserving shareholder capital long term.
Bears Say
Pre-revenue With Sizable Operating LossesBeing pre-revenue with large negative operating results means the company lacks self-sustaining cash generation. Over a multi-month horizon this structurally necessitates external financing or partnerships to fund pivotal trials, increasing dilution risk and tying corporate progress to successful clinical readouts.
Negative And Pressured Cash Flow; Funding ReliancePersistent negative operating and free cash flow create a structural dependency on outside capital. While burn has improved, the lack of steady positive cash flow means near‑term operations and trial progression hinge on financing execution, which can constrain strategy and lead to unfavorable terms.
Declining Equity Base And Very Negative ROEA shrinking equity base combined with deeply negative ROE signals poor capital efficiency and cumulative dilution. Over several months this erodes shareholders' stake and limits the firm's ability to absorb setbacks, increasing vulnerability to dilutive financings or strategic alternatives if clinical timelines slip.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.55 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $84.13M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 23 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.018.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 89,498,020 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 4.31%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (194.12% Upside)
$3.50 (194.12% Upside)
Hedge Fund Trend
Decreased
By 151.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $32.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
-72.68%
Trailing 12-Months
Asset Growth
53.79%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Stock 12 Month Forecast
Average Price Target
$3.50
▲(194.12% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
10.81% Insiders
4.31% Mutual Funds
0.06% Other Institutional Investors
80.75% Public Companies and
Individual Investors